SRX3207

立即咨询

SRX3207

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2254693-15-5

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议
200mg	电议
500mg	电议

产品介绍

SRX3207 是具有口服活性的、首创的Syk/PI3K双抑制剂，其对 Syk 和 PI3Kα 的IC₅₀值分别为 10.7 nM 和 861 nM。SRX3207 缓解抗肿瘤免疫抑制。

生物活性

SRX3207 is an orally active and first-in-class dualSyk/PI3Kinhibitor, withIC₅₀values of 10.7 nM and 861 nM forSykandPI3Kα, respectively. SRX3207 relieves tumor immunosuppression^[1]^[2].

IC₅₀& Target^[2]

Syk

10.7 nM (IC₅₀)

PI3Kα

861 nM (IC₅₀)

PI3Kδ

1280 nM (IC₅₀)

PI3Kγ

11100 nM (IC₅₀)

Zap70

1300 nM (IC₅₀)

体外研究
(In Vitro)

SRX3207 (10 μmol/L) is able to block p-AKT at concentration^[1].
SRX3207 has sufficient solubility in water (43 μmol/L)^[1].

体内研究
(In Vivo)

SRX3207 (10 mg/kg, orally) increases antitumor immune response^[1].

Animal Model:	LLC or B16 or B16-OVA or CT26 (1 × 10⁵) cells were injected subcutaneously into syngeneic mice^[1].
Dosage:	10 mg/kg.
Administration:	Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21.
Result:	Blocked phosphorylation of Syk at 348 site and Y525/526 site. Blocked immunosuppressive MΦ polarization. Blocked tumor growth and increased survival effectively.

分子量

555.65

性状

Solid

Formula

C₂₉H₂₉N₇O₃S

CAS 号

2254693-15-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 5 mg/mL(9.00 mM;Need ultrasonic)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	1.7997 mL	8.9985 mL	17.9969 mL
5 mM	0.3599 mL	1.7997 mL	3.5994 mL
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。